drugset / Trial / NCT00755378

AZD8529 Single Ascending Dose Study

NCT00755378

Phase 1 Completed 58 enrolled AstraZeneca
RandomizedSingle-groupQuadruple-blind

Summary

This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after single ascending doses

Timeline

Start
2008-09
Primary completion
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8529 Other / unclassified Oral

Indications

No indication recorded.